@entity2643 -induced @entity2743 presenting as XXXX periodic @entity912 .

@entity1 @entity1375 @entity2643 @entity972 @entity1931 @entity353 @entity1760 @entity2743 @entity3937 @entity3157 @entity425 @entity400 @entity460 @entity8598 @entity912 @entity1374
@entity1374 is a well-recognized side effect of @entity2643 therapy. @entity2743 is less common than @entity1375 . @entity8598 periodic @entity912 is one manifestation of @entity2743 , and is more often seen in Oriental and Latin American @entity1 than in other demographic groups. This phenomenon, however, has not been previously described in @entity2743 due to @entity2643 usage. We describe a case of @entity2643 -induced @entity2743 in a 34-year-old @entity1 who presented with @entity425 , @entity1931 , and @entity353 . Physical examination demonstrated fine @entity400 . Serum @entity972 level was 2.2 mEq/L on admission. Gastrointestinal and renal causes of @entity972 loss were excluded by history and physical examination. Further biochemical testing demonstrated @entity1374 . The urinary @entity972 and serum @entity3157 , @entity1760 , and @entity460 levels were within normal limits. Lower extremity @entity425 resolved immediately after @entity972 replacement therapy. @entity3937 therapy was initiated, and the @entity1 was clinically euthyroid on discharge.
